SCHEMBL22979094

SCHEMBL22979094

COc1ccc(-c2nc3c4ccccc4[nH]c(=O)n3n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 1.00
ALDH1A1 P00352 2/20 1.00
POLB P06746 1/20 1.00
TP53 P04637 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
RXFP1 Q9HBX9 1/20 0.76
GABRP O00591 1/20 0.74
GABRD O14764 1/20 0.74
GABRA1 P14867 1/20 0.74
GABRB1 P18505 1/20 0.74
GABRG2 P18507 1/20 0.74
GABRB3 P28472 1/20 0.74
GABRA5 P31644 1/20 0.74
GABRA3 P34903 1/20 0.74
GABRA2 P47869 1/20 0.74
GABRB2 P47870 1/20 0.74
GABRA4 P48169 1/20 0.74
GABRE P78334 1/20 0.74
GABRA6 Q16445 1/20 0.74
GABRG1 Q8N1C3 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29646388 1.00 KDM4E (1.00) KDM4EALDH1A1POLBTP53SMN1; SMN2
SCHEMBL22987532 0.88 KDM4E (0.78) KDM4EALDH1A1POLBTP53SMN1; SMN2
SCHEMBL22988100 0.88 KDM4E (0.78) KDM4EALDH1A1POLBTP53SMN1; SMN2
SCHEMBL22979083 0.87 KDM4E (0.77) KDM4EALDH1A1POLBTP53SMN1; SMN2
SCHEMBL29646465 0.87 KDM4E (0.77) KDM4EALDH1A1POLBTP53SMN1; SMN2
SCHEMBL29646386 0.86 TP53 (1.00) KDM4EALDH1A1POLBTP53SMN1; SMN2
SCHEMBL22980133 0.86 TP53 (1.00) KDM4EALDH1A1POLBTP53SMN1; SMN2
SCHEMBL10712254 0.86 GABRP (1.00) KDM4EALDH1A1POLBTP53SMN1; SMN2
SCHEMBL29646479 0.86 GABRP (1.00) KDM4EALDH1A1POLBTP53SMN1; SMN2
SCHEMBL22979004 0.85 ALDH1A1 (0.74) KDM4EALDH1A1POLBTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 KDM4E 1364/4885ALDH1A1 597/4885POLB 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.